EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study

Wynne Zheng iD, Maeen Arslan, Christina Zhu iD, Christopher Guirguis, Daniel B Spielman

Laryngoscope Investigative Otolaryngology · 2026-04 · 11 (2)

DOI: 10.1002/lio2.70304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngoscope Investigative Otolaryngology, online erschienen am 02.04.2026. Verfasst von Wynne Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown University School of Medicine Washington DC USA. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess whether biologics (dupilumab, mepolizumab, and omalizumab) used for conditions other than chronic rhinosinusitis with nasal polyps (CRSwNP) reduce the frequency of acute bacterial rhinosinusitis (ABRS) episodes.

Methods

This retrospective cohort study utilized the All of Us Research Program database to identify patients treated with dupilumab, mepolizumab, or omalizumab, excluding those with CRSwNP. A control group matched by race, gender, and comorbidities (asthma, allergic rhinitis, atopic dermatitis, smoking status) was created using propensity score matching (1:1 ratio) and K‐nearest neighbors. The primary outcome was the frequency of ABRS episodes in biologic‐exposed versus control groups, analyzed using χ 2 tests to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

Results

Out of 2094 subjects, the biologic group had a significantly lower ABRS rate (6%) compared to controls (14%) (OR 0.4349, p < 0.0001). Dupilumab use was associated with the greatest significant reduction in ABRS risk (OR 0.1526, p < 0.001044). Mepolizumab (OR 0.6027, p = 1) and omalizumab (OR 0.7671, p = 0.4133) showed a decrease in ABRS episodes though this finding was not statistically significant.

Conclusion

Dupilumab appears to significantly reduce ABRS episodes in patients without CRSwNP, suggesting a protective effect on sinonasal health even in patients without chronic sinusitis. Further studies are needed to confirm these effects and to evaluate risks associated with long‐term biologic use in non‐CRSwNP populations. Level of Evidence IIIb/IV.

Schlagwörter

Stichwörter der Autor:innen

acute rhinosinusitisbiologic medicationchronic rhinosinusitisnasal polyps

Autor:innen und Institutionen

  • Georgetown University School of Medicine Washington DC USA.
  • Department of Otolaryngology MedStar Georgetown University Hospital Washington DC USA.

ORCID-Profile: Wynne Zheng, Christina Zhu

Zitieren

APA

Zheng, W., Arslan, M., Zhu, C., Guirguis, C., & Spielman, D. B. (2026). Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study. Laryngoscope Investigative Otolaryngology, 11(2). https://doi.org/10.1002/lio2.70304

Vancouver

Zheng W, Arslan M, Zhu C, Guirguis C, Spielman DB. Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study. Laryngoscope Investigative Otolaryngology. 2026;11(2). doi:10.1002/lio2.70304

BibTeX
@article{Zheng2026,
  author = {Zheng, Wynne and Arslan, Maeen and Zhu, Christina and Guirguis, Christopher and Spielman, Daniel B},
  title = {Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study},
  journal = {Laryngoscope Investigative Otolaryngology},
  year = {2026},
  volume = {11},
  number = {2},
  doi = {10.1002/lio2.70304}
}
Kostenlos starten →